Skip to main content
. Author manuscript; available in PMC: 2018 Mar 26.
Published in final edited form as: J Med Virol. 2015 Aug 31;88(2):312–318. doi: 10.1002/jmv.24331

Fig. 1.

Fig. 1

IBD patients on anti-TNFα have fewer T and NK cells and improvement in inflammatory markers. PBMC from patients and control subjects were immunostained and CD2+ cells enumerated by FACS in A. Inflammatory markers, erythrocyte sedimentation rate and c-reactive protein, before (black bars) and after (open bars) anti-TNFα therapy are shown in B. Data represent mean +/− SEM.